You just read:

Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

News provided by

Ipsen Biopharmaceuticals, Inc.

01 Aug, 2016, 08:00 ET